Patents by Inventor Douglas G. Batt

Douglas G. Batt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20120058996
    Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation.
    Type: Application
    Filed: November 9, 2011
    Publication date: March 8, 2012
    Inventors: Qingjie Liu, Douglas G. Batt, George V. DeLucca, Qing Shi, Andrew J. Tebben
  • CARBAZOLE AND CARBOLINE KINASE INHIBITORS
    Publication number: 20120058988
    Abstract: The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof The Formula (I) compounds inhibit tyrosine kinase activity of Jak2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Application
    Filed: December 17, 2009
    Publication date: March 8, 2012
    Inventors: Ashok Vinayak Purandare, Douglas G. Batt, Qingjie Liu, Harold Mastalerz, Kurt Zimmermann
  • Carbazole carboxamide compounds useful as kinase inhibitors
    Patent number: 8084620
    Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: December 27, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qingjie Liu, Douglas G. Batt, George V. DeLucca, Qing Shi, Andrew J. Tebben
  • CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20110118354
    Abstract: The present application describes modulators of MCP-1 or CCR-2 of formula, (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein T, W, X, Y, Z, R1, R2, R4 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula, (I) are disclosed.
    Type: Application
    Filed: July 14, 2009
    Publication date: May 19, 2011
    Inventors: Percy H. Carter, Gregory D. Brown, George V. De Lucca, Douglas G. Batt, Rui-Qin Liu, Feng Qiu
  • CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20110112146
    Abstract: The present application describes modulators of MCP-1 or CCR-2 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W1, W2, W3, Y, Z, R2, R3, R3? and R4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
    Type: Application
    Filed: July 14, 2009
    Publication date: May 12, 2011
    Inventor: Douglas G. Batt
  • Cyclic derivatives as modulators of chemokine receptor activity
    Patent number: 7829571
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: November 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Percy H. Carter, Robert J. Cherney, Douglas G. Batt, John V. Duncia, Daniel S. Gardner, Soo S. Ko, Anurag S. Srivastava, Michael G. Yang
  • CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20100160303
    Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation.
    Type: Application
    Filed: December 17, 2009
    Publication date: June 24, 2010
    Inventors: Qingjie Liu, Douglas G. Batt, George V. DeLucca, Qing Shi, Andrew J. Tebben
  • CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20090124668
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 14, 2009
    Inventors: Percy H. Carter, Robert J. Cherney, Douglas G. Batt, John V. Duncia, Daniel S. Gardner, Soo S. Ko, Anurag S. Srivastava, Michael G. Yang
  • Cyclic derivatives as modulators of chemokine receptor activity
    Patent number: 7482335
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: January 27, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Percy H. Carter, Robert J. Cherney, Douglas G. Batt, John V. Duncia, Daniel S. Gardner, Soo S. Ko, Anurag S. Srivastava, Michael G. Yang
  • Substituted spiro azabicyclics as modulators of chemokine receptor activity
    Patent number: 7479496
    Abstract: The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5?, R6, a, b, c, d, and u are as defined herein in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using modulators of formula (Ia) and (Ib) are disclosed.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: January 20, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G. Batt, Dean A. Wacker, George V. De Lucca
  • Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
    Patent number: 7381738
    Abstract: The present application describes modulators of MCP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein X, Z, a, b, c, d, n, R1, R2, R3, R4, R5, R10, R10a, and R12, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using modulators of formula (I) are disclosed.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: June 3, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G. Batt, Percy H. Carter
  • Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
    Patent number: 7378409
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: May 27, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Percy H. Carter, Robert J. Cherney, Douglas G. Batt, Gregory D. Brown, John V. Duncia, Daniel S. Gardner, Michael G. Yang
  • N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
    Patent number: 7291744
    Abstract: The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: November 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soo S. Ko, Douglas G. Batt, George V. Delucca, John V. Duncia, Daniel S. Gardner, Joseph B. Santella
  • Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
    Patent number: 7288563
    Abstract: The present application describes modulators of MCP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein X, Z, a, b, c, d, bond g, n, s, R1, R2, R4, R5, R10, R12, and R13, are as defined above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: October 30, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G. Batt, Percy H. Carter
  • Substituted fused bicyclic amines as modulators of chemokine receptor activity
    Patent number: 7230022
    Abstract: The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5?, R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: June 12, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G. Batt, Percy H. Carter, Dean A. Wacker
  • Cyclic derivatives as modulators of chemokine receptor activity
    Patent number: 7163937
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: January 16, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Percy H. Carter, Robert J. Cherney, Douglas G. Batt, John V. Duncia, Daniel S. Gardner, Soo S. Ko, Anurag S. Srivastava, Michael G. Yang
  • N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6949546
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: September 27, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, James R. Pruitt, Dean A. Wacker, Douglas G. Batt
  • N-substituted heterocyclic amines as modulators of chemokine receptor activity
    Patent number: 6919356
    Abstract: The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: July 19, 2005
    Assignee: Bristol Myers Squibb Company
    Inventor: Douglas G. Batt
  • N-substituted heterocyclic amines as modulators of chemokine receptor activity
    Publication number: 20040067935
    Abstract: The present application describes modulators of chemokine receptors of formula (I): 1
    Type: Application
    Filed: September 25, 2003
    Publication date: April 8, 2004
    Inventor: Douglas G. Batt
  • N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
    Publication number: 20040058961
    Abstract: The present application describes modulators of CCR3 of formula (I): 1
    Type: Application
    Filed: July 10, 2003
    Publication date: March 25, 2004
    Inventors: Soo S. Ko, James R. Pruitt, Dean A, Wacker, Douglas G. Batt